Emergency Care

Our Emergency Care Trials

CRASH-2 (complete)

Results showed that tranexamic acid safely reduced the risk of death in bleeding trauma patients

CRASH-3 (complete)

The CRASH-3 trial is the first evidence of a drug which can prevent death following Traumatic Brain Injury (TBI)

CRASH-4 (Pilot Study - ongoing)

The effects of early intramuscular (IM) tranexamic acid (TXA) treatment on dementia, disability and death in older adults with mild traumatic brain injury (TBI)

CRASH-19 (recruitment not started)

Aim to assess the effectiveness and safety of supportive care interventions for patients hospitalised with suspected or confirmed acute COVID-19 infection with a focus on cardiac and pulmonary protection. We will evaluate the effects of aspirin, the angiotensin receptor blocker losartan, and simvastatin compared with standard care.

** Recruitment not started due to lack of funding**

BRAIN Trial (complete)

Bradykinin B2 Receptor Antagonist (Anatibant) in Neurotrauma: A phase II randomised, double blind, placebo-controlled, dose finding, safety and tolerability trial of XY2405 as a treatment for traumatic brain injury

Halt-IT (complete)

The HALT-IT trial assessed whether administration of tranexamic acid (TXA) in people with acute gastrointestinal bleeding can reduce their risk of dying in hospital

Trauma - INTACT (complete)

Trauma-INTACT results show that TXA is well tolerated and rapidly absorbed via the IM route in bleeding trauma patients

WOMAN Trial (complete)

Tranexamic acid for the treatment of postpartum haemorrhage: An international, randomised, double blind, placebo controlled trial. The WOMAN trial showed that if given within 3 hours, TXA can reduce the risk of death due to bleeding by one third

Are you interested in collaborating on one of our ongoing trials? Email enquiries to ctu@lshtm.ac.uk

Our Funders